Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

A few months later, Biogen brought tofersen back to life with a fresh analysis of data from that trial plus an open-label extension – in an echo of the approach it took with ill-fated Alzheimer ...

Stoke could get up to $385 million in development and commercial milestone payments, plus potential tiered royalties on zorevunersen sales in Biogen’s territory. Biogen will support zorevunersen ...

Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of ...

Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell Stoke’s experimental treatment for Dravet syndrome, a severe form of epilepsy, outside the U.S., the ...

and is thought to have the greatest commercial potential of the two with a chance of $1 billion-plus sales at peak. Qalsody, meanwhile, has been tipped to make around $300 million. Biogen acquired ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be ...

Biogen expects full-year 2025 total revenue to decline by a mid-single digit percentage. The company’s stock was down about 6% at 10 a.m. on Wednesday with shares priced at around $131 apiece.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Stoke will receive $165m upfront from Biogen upon completion of the transaction. The company is eligible for up to $385m in development and commercial milestone payments, plus tiered royalties on ...